Observational Study Evaluating Efficacy, Tolerability and Treatment Algorithm of Advanced Renal Cell Cancer Patients Under Afinitor Treatment.

Trial Profile

Observational Study Evaluating Efficacy, Tolerability and Treatment Algorithm of Advanced Renal Cell Cancer Patients Under Afinitor Treatment.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Jan 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms OSAT
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 12 Jan 2016 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 04 Nov 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 04 Nov 2014 Planned primary completion date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top